Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride

Radioligand therapy with (177)Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with (223)Ra-dichloride as a single th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadzadehfar, Hojjat, Zimbelmann, Stefanie, Yordanova, Anna, Fimmers, Rolf, Kürpig, Stefan, Eppard, Elisabeth, Gaertner, Florian C., Wei, Xiao, Hauser, Stefan, Essler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589682/
https://www.ncbi.nlm.nih.gov/pubmed/28903443
http://dx.doi.org/10.18632/oncotarget.15698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589682/
https://www.ncbi.nlm.nih.gov/pubmed/28903443
http://dx.doi.org/10.18632/oncotarget.15698

Ejemplares similares